Since the original publications by Hench and his colleaguesl 2 on the use of cortisone and ACTH in the treatment of rheumatoid arthritis, corticosteroid drugs have assumed an important role in the therapy of a large number of diseases, including diseases of the liver and gastrointestinal tract. Although the precise mode of action of these agents is uncertain, there is increasing evidence that their beneficial effects result from actions on immunological and inflammatory processes. An understanding of such effects and of the clinical pharmacology of the corticosteroid drugs should lead to a more rational approach to therapy. This is particularly important in treating patients with liver disease who are prone to the unwanted effects of corticosteroid therapy and in whom the metabolism of these drugs may be altered.
The aims of this paper are threefold: firstly, to outline the biochemical pharmacology of the corticosteroid drugs relevant to the clinical management of gastrointestinal and liver disease; secondly, to review current knowledge of the immunological and anti-inflammatory effects of these agents; and, thirdly, to discuss the use of prednisone and prednisolone in the management of a number of hepatic diseases. Although the basis of therapy of corticosteroids is probably similar in gastrointestinal and liver diseases, the indications for the use of corticosteroids in gastrointestinal diseases are less clearly defined and are not discussed here.
Pharmacology of corticosteroid drugs
Various biochemical manipulations of the corticosteroid molecule have resulted in differing glucocorticoid or mineralocorticoid activity, but cumulative toxic effects remain the major problem of long-term corticosteroid therapy. Corticosteroids have been shown to interact with receptor proteins in the cytoplasm of cells3 and alteration of protein synthesis follows interaction of the glucocorticoid: receptor complex with nuclear DNA.4 However, it has been proposed that corticosteroids have effects on cells that are mediated through other mechanisms. One such mechanism postulates alteration of cell surface characteristics, and this may be responsible for the rapid alterations in lymphocyte kinetics observed after the administration of corticosteroids.5 For instance, corticosteroids have been shown to alter the expression of cellular IgG and complement receptors, and the locus of action in these studies appears to be at the membrane level.6 Studies using lysosomes also support a direct action at membrane level.7 Complex interactions between cyclic nucleotides and glucocorticoids on the physiology of cells have been demonstrated.8 Although cAMP does not act as an intracellular 'second message' for the mediation of glucocorticoid action, cortisol has been shown to activate adenyl cyclase in human leucocytes9 10 and this may have a significant influence on the state of activation of these cells, especially those of the monocyte/macrophage system.11
Prednisone has very little intrinsic glucocorticoid activity,12 and has to be converted in the liver to the biologically active metabolite, prednisolone. In severe liver failure some impairment of this conversion may occur, but it is comparatively trivial.'3 In a detailed pharmacokinetic study, Schalm and his colleagues13 showed that serum prednisolone levels were significantly lower in patients with impaired liver function than in others, but there was also a greater percentage of pharmacologically active, unbound drug present in the serum under such circumstances. An additional factor to be taken into account in this situation is impairment of hepatic A ring reduction, resulting in decreased elimination of the active metabolite.'4 '5 Thus, impaired conversion of prednisone to prednisolone in severe liver failure may be compensated for by a decreased rate of elimination of the active metabolite as well as by decreased protein binding. Schalm and his colleagues concluded that failure of some patients with chronic hepatitis to respond to prednisone treatment could not be attributed to the small differences in conversion of prednisone to prednisolone associated with severe impairment of liver function. However, there are occasional individuals who show a marked impairment in the conversion of prednisone to prednisolone,'4 and most authors accept that it is probably best to administer prednisolone rather than prednisone to all patients with liver disease, if only because the serum levels achieved are more predictable.
The elimination half-life of prednisolone from plasma remains constant (3-5±0-2h) over the conventional dosage range (5-100 mg) and this closely correlates with the tissue half-life which is approximately one and a half to twice the plasma elimination half-life. '6 It is the tissue half-life which most closely relates to therapeutic efficacy and long-term toxic effects. '6 Monocyte chemotaxis is similarly impaired in the presence ofcorticosteroids36 although monocytes isolated from subjects on corticosteroids exhibit normal chemotactic responses in vitro.29 Monocyte bactericidal activity is depressed by corticosteroids.29 However, the most important aspect of monocyte function that is altered by corticosteroids is their ability to respond to lymphokines. These are chemical messengers liberated by lymphocytes on exposure to certain antigens and mitogens, and they modify the behaviour and recruitment of other cells involved in the immune response. Some of the most important lymphokines identified alter monocyte activity such as migration inhibition factor (MIF), macrophage arming factor (MAF) and macrophage chemotactic factor (MCTF). There is evidence that, in general, lymphokine production is uninfluenced by corticosteroids,37 38 although some work suggests that corticosteroids can depress the production of certain lymphokines, in particular macrophage chemotactic factor.39 However, the ability o' monocytes to respond to liberated lymphokines is markedly suppressed.37 38 This may be mediated by alterations in the surface group.bmj.com on June 15, 2017 -Published by http://gut.bmj.com/ Downloaded from receptors of the monocyte.
As indicated above, corticosteroid administration causes a transient lymphocytopenia with counts returning to normal by 24 hours.28 There is a decrease in both T and B lymphocyte numbers, although there is a disportionately greater decrease of circulating T lymphocytes.28 This depletion almost certainly represents redistribution into other body compartments rather than lysis.40 Some subpopulations of lymphocytes may show differing sensitivities to corticosteroids, as it has been shown that circulating 'null' cells (lymphocytes with neither E nor EAC surface markers) are not decreased after prednisone administration.4' It has also been noted that there are differential effects of different corticosteroid preparations on lymphocyte function. For instance, dexamethasone administration results in suppression of PHA-induced cellular cytotoxicity when lymphocytes are assessed four hours after administration; yet equivalent 'anti- (MIF) and macrophage arming factor (MAF) are released normally by lymphocytes, the monocyte-macrophage response to these liberated factors is impaired in the presence of corticosteroids.37 38 One illustrative consequence of this may be the reduction of delayed skin reactivity in patients on corticosteroids. Additional effects of corticosteroids that have been demonstrated include impairment of particulate antigen processing by macrophages,44 and diminution of T lymphocyte cytotoxic activity by prior exposure of these cells to corticosteroids.45 This latter effect has been shown to be independent of RNA, DNA, or protein synthesis and is reversed by subsequent exposure to concanavalin A. This suggests that the site of action of corticosteroids in this situation is at the membrane level, being independent of glucocorticoid receptor interaction.
In summary, the circulation kinetics and access of leucocytes to sites of potential immunological reactions are suppressed and the interaction of effector cells with the soluble products of activated lymphocytes are antagonised, resulting in marked suppression of cell-mediated immune responses. The influences of corticosteroids on monocytes and lymphocytes are sum- Some actions of corticosteroids are predominantly anti-inflammatory, such as their influence on vascular permeability,51 and their alteration of the response to local mediators of inflammation such as kinins52 and histamine,48 but other influences are predominantly immunosuppressive (Table 2) . Decreased lymphocyte and monocyte function (Table 1) Although immunosuppressive activity may result in anti-inflammatory activity, the importance of either influence remains to be elucidated in many disease states. A separate effect that may have some relevance in human liver disease is the suppression of collagen formation by inhibition of proline hydroxylase activity. 54 Although this has been demonstrated in experimental liver injury, no studies to date have shown that this is of significant clinical benefit to man.
With regard to hepatitis, the role of infiltrating mononuclear cells as the cause of cell death has been pursued in a number of studies. Lymphocyte cytotoxicity for a variety of liver cell lines in tissue culture has been demonstrated in chronic active liver disease (CALD), although this has not been shown to be a specific finding (see review by Smith, C.J. et al.55) However, it does seem likely that lymphocytes from patients with a variety of liver disorders are sensitised to one or more antigens found in normal liver tissue. Lymphocytes from patients with alcoholic hepatitis have shown 'in vitro' cytotoxicity for rabbit hepatocytes, possibly reflecting sensitivity to a liverspecific membrane lipoprotein.56 It may therefore be relevant that corticosteroids have been shown to diminish lymphocyte cytotoxic activity.45
A recent paper has provided evidence that mononuclear phagocytes already recruited into the liver by other processes may release factors toxic for hepatocytes on exposure to endotoxin, thus perpetuating tissue injury.57 The ability of endotoxin to activate macrophages in this situation may be reduced by corticosteroids, as these drugs have been shown to protect against endotoxin-induced shock.58 Thus it may be appreciated that corticosteroid therapy in liver disease may influence the course of the illness through a wide variety of anti-inflammatory and immune mechanisms, and, until precise knowledge of the pathogenesis of these diseases is apparent, the mechanism of action of corticosteroids remains speculative.
Effect of prednisolone on normal hepatic function and tests of liver function In the hepatic conditions to be considered, the influence of prednisolone on the course of the illness has been judged either on clinical grounds or on the basis of changes in biochemical tests. This latter area has been investigated in normal subjects,59 and, although there was a significant decrease in the conjugated bilirubin concentration during prednisolone treatment, there was no alteration in quantitative tests of liver function (galactose elimination capacity, bromsulfphthalein transport maximum and storage capacity). There was a significant rise in GPT and IgM concentrations, but no value became abnormal. All other enzymes and serum proteins remained unchanged during prednisolone therapy. Urinary D-glucaric acid output also remained unchanged, suggesting that prednisolone had little effect on the state of hepatic enzyme induction. Although caution should be exercised in extrapolating these results to patients with chronic liver disease, they show that prednisolone administration does not appear to interfere with the interpretation of these tests.
Use of corticosteroids in liver disease VIRAL 
HEPATITIS
As early as 1937, it was suggested by Eppinger that adrenal cortical hormones might be beneficial in the treatment of hepatic diseases. Initial studies of the use of corticosteroids in viral hepatitis indicated that they might be of some benefit,60 61 but as early as 1953 it was suggested that this form of therapy made the patient more vulnerable to relapse.62 Of 117 control patients, none relapsed, whereas two of 10 patients treated with cortisone relapsed. Although these figures are unbalanced and retrospective, this study has been subsequently confirmed in a paper from Switzerland, where a relapse rate of 15 % was noted in the steroid-treated group (101 subjects) as against 1 % in the placebo group (275 subjects)63. In addition, the steroid-treated group were more prone to peptic ulceration and pyogenic infections. A feature of all these early studies was the more rapid resolution of raised serum levels of bilirubin in the steroid-treated groups. A case has been made by a number of authors for the treatment with corticosteroids of viral hepatitis with prolonged cholestasis as the period ofjaundice is shortened. The opposing view has been expressed, but review of the biochemistry and histology of the patients in this report66 suggests that at least two of the four patients studied had chronic active hepatitis. Relapses are likely if the steroids are withdrawn too soon and treatment, if instigated, should be continued well into convalescence and until the serum bilirubin level is normal.64 With the exception of prolonged cholestasis, corticosteroids are contraindicated in uncomplicated viral hepatitis.67 FULMINANT HEPATITIS There has been considerable controversy over the years concerning the place of corticosteroids in the management of fulminant hepatic failure. In 1962 it was reported that corticosteroids might have a favourable influence on the outcome of patients with acute hepatitis in coma,68 but other reports were unable to confirm these findings.69-7' In 1976 a double-blind prospective study of the use of methylprednisolone in severe viral hepatitis was published and the authors concluded 'that corticosteroid therapy did not enhance survival in patients with severe viral hepatitis and that it may be deterimental72. In the ensuing correspondence there was some criticism of the comparability of the two groups and of the fact that survival in the placebo group was over 80%.73 This figure suggests that these were not patients with fulminant hepatitis but that they had a less severe form of hepatitis. However, other correspondence has provided additional figures on survival in other groups of patients with support for the contention that corticosteroids are of no value in fulminant hepatitis. 71 The likelihood of a type II statistical error in this study72 is very small indeed. In a preliminary report from the USA Acute Hepatic Failure Study Group,74 no benefit for corticosteroid therapy has been demonstrated after analysis of the results from the first 57 patients randomised and considered eligible. A smaller unblinded, European multicentre study75 has produced similar results. Survival was 12% in the corticosteroid-treated group (26 subjects) compared with 14% in the placebo group (14 subjects).
Although there are differences in disease severity, entry criteria, and therapy in all these studies, the general consensus at present is firmly against the use of corticosteroids in fulminant hepatitis. Indeed, combining results from the four randomised trials70 71 72 75 gives strong evidence of a negative effect (P < 0.02).
CHRONIC ACTIVE HEPATITIS
There have been three major studies published in the past 10 years demonstrating a beneficial effect of corticosteroids in chronic active hepatitis (CAH), both in terms of disease activity and of mortality. [76] [77] [78] The Mayo Clinic has reported that two-thirds of a group of patients with CAH being treated with steroids suffered one or more serious complications group.bmj.com on June 15, 2017 -Published by http://gut.bmj.com/ Downloaded from of steroid therapy. 84 It therefore seems that those patients in whom the benefits of steroid therapy outweigh the incidence of serious side effects need to be precisely defined.
It should be noted that, of the three widely quoted trials,78-78 only two were able to test for HBsAg and that the incidence of this marker was surprisingly low, probably reflecting the relatively insensitive methods of detection available at the time. In the quoted trials, and especially the Mayo Clinic study, a large number of patients were symptomatic and a large proportion were cirrhotic at the time of entry to the study. In addition, the biochemical abnormalities required for entry to this study showed that this group had particularly severe disease (AST 10 x normal or AST 5 x normal, together with a serum y globulin level 2 x normal). This is in contrast with the present situation, where a substantial proportion of patients diagnosed as having CAH are asymptomatic85 and pre-cirrhotic with less markedly abnormal biochemical parameters.
However, all of the above three studies of corticosteroid therapy of patients with CAH arrived at similar conclusions, and in an elegant analysis of these studies Wright et al. come to the conclusion 'that corticosteroid therapy only outweighs its potential toxicity in those who are symptomatic, who are HBsAg-negative and who have severe histological abnormalities (subacute hepatitis with multilobular necrosis or active cirrhosis)'86. The risk to benefit ratio is unknown in patients who are HBsAg-positive or clinically well persons and routine administration of corticosteroids to these subgroups may not be justified. However, each patient needs to be assessed on an individual basis, as there may well be a number of patients in these categories who benefit from steroid therapy.
In those patients with chronic active hepatitis who benefit from steroid therapy, it has been shown that a daily combination of prednisone (10 mg) and azathioprine (50 mg) after an initial month of higher prednisone dose offers the best chance of disease control combined with the lowest incidence (10%) of major steroid side-effects.84 Current advocacy of alternate day steroid regimes has led to their assessment in this condition. Titration of alternate day dosage to secure biochemical and clinical resolution does increase early survival, but the incidence of severe complications is considerably higher (36%) than in the group treated with the fixed combination outlined above.84 In addition, histological resolution of the disease occurred less frequently in the 'alternate day' treated patients. A recent study recommends the use of prednisolone rather than prednisone, as the serum levels are more predictable. '4 Relapse tends to be treated in an empirical manner, and additional studies are necessary to determine the appropriate use of corticosteroids in this situation. However, it has been shown that 50% of those with severe disease will relapse if corticosteroids are discontinued within six months of remission induction, whereas the relapse rate falls to 8 % if treatment is continued beyond six months." 87 It seems that only a minority require continuous steroid therapy for longer than three years,88 but guidelines have still to be precisely determined.
Late results of the outcome of treatment with corticosteroids of an early group of patients have recently been published by the Royal Free group in abstract form.89 The mean duration of treatment with corticosteroids was 4.5 years. Age, presence of antinuclear factor, cirrhosis, or level of transaminases at presentation were not prognostic factors, although male patients untreated did less well than female patients. Ten-year survival in the treatment group was 63 %, compared with 27 % in the control group (P =0'03) with a median survival of 12-2 years in the former group, compared with 3-3 years in the latter.
CHRONIC PERSISTENT HEPATITIS
There is general agreement that corticosteroid therapy is not indicated in those patients with chronic persistent hepatitis, as the condition is virtually asymptomatic, non-progressive, and associated with a good prognosis.,* However, sampling error on liver biopsy can lead to an erroneous diagnosis in a patient with chronic active hepatitis. 
